220 related articles for article (PubMed ID: 11014949)
1. Effects of a vasopressin antagonist in women with dysmenorrhea.
Valentin L; Sladkevicius P; Kindahl H; Broeders A; Marsal K; Melin P
Gynecol Obstet Invest; 2000; 50(3):170-7. PubMed ID: 11014949
[TBL] [Abstract][Full Text] [Related]
2. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea.
Liedman R; Grant L; Igidbashian S; James I; McLeod A; Skillern L; Akerlund M
Acta Obstet Gynecol Scand; 2006; 85(2):207-11. PubMed ID: 16532916
[TBL] [Abstract][Full Text] [Related]
3. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
4. Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study.
Akerlund M
Acta Obstet Gynecol Scand; 1987; 66(5):459-61. PubMed ID: 3321865
[TBL] [Abstract][Full Text] [Related]
5. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin.
Akerlund M; Carlsson AM; Melin P; Trojnar J
Acta Obstet Gynecol Scand; 1985; 64(6):499-504. PubMed ID: 4061066
[TBL] [Abstract][Full Text] [Related]
6. Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban.
Bossmar T
J Perinat Med; 1998; 26(6):458-65. PubMed ID: 10224602
[TBL] [Abstract][Full Text] [Related]
7. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects.
Liedman R; Hansson SR; Howe D; Igidbashian S; McLeod A; Russell RJ; Akerlund M
Gynecol Endocrinol; 2008 Sep; 24(9):508-13. PubMed ID: 18958771
[TBL] [Abstract][Full Text] [Related]
8. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist.
Hauksson A; Akerlund M; Melin P
Br J Obstet Gynaecol; 1988 Sep; 95(9):898-904. PubMed ID: 3191063
[TBL] [Abstract][Full Text] [Related]
9. Effect of the oxytocin antagonist atosiban (1-deamino-2-D-tyr(OET)-4-thr-8-orn-vasotocin/oxytocin) on nocturanl myometrial contractions, maternal cardiovascular function, transplacental passage, and fetal oxygenation in the pregnant baboon during the last third of gestation.
Nathanielsz PW; Honnebier MB; Mecenas C; Jenkins SL; Holland ML; Demarest K
Biol Reprod; 1997 Aug; 57(2):320-4. PubMed ID: 9241045
[TBL] [Abstract][Full Text] [Related]
10. Validation of a test model of induced dysmenorrhea.
Liedman R; Skillern L; James I; McLeod A; Grant L; Akerlund M
Acta Obstet Gynecol Scand; 2006; 85(4):451-7. PubMed ID: 16612708
[TBL] [Abstract][Full Text] [Related]
11. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.
Chen YL; Shepherd C; Spinelli W; Lai FM
Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088
[TBL] [Abstract][Full Text] [Related]
12. Traditional Chinese medicine Guizhi Fuling capsule used for therapy of dysmenorrhea via attenuating uterus contraction.
Sun L; Liu L; Zong S; Wang Z; Zhou J; Xu Z; Ding G; Xiao W; Kou J
J Ethnopharmacol; 2016 Sep; 191():273-279. PubMed ID: 27340106
[TBL] [Abstract][Full Text] [Related]
13. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban.
Bossmar T; Akerlund M; Fantoni G; Szamatowicz J; Melin P; Maggi M
Am J Obstet Gynecol; 1994 Dec; 171(6):1634-42. PubMed ID: 7802081
[TBL] [Abstract][Full Text] [Related]
14. Anemia-related hemogram, uterine artery pulsatility index, and blood pressure for the effects of Four-Agents-Decoction (Si Wu Tang) in the treatment of primary dysmenorrhea.
Yeh LL; Liu JY; Liu YS; Lin KS; Tsai TF; Wang LH
J Altern Complement Med; 2009 May; 15(5):531-8. PubMed ID: 19413507
[TBL] [Abstract][Full Text] [Related]
15. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women.
Akerlund M; Hauksson A; Lundin S; Melin P; Trojnar J
Br J Obstet Gynaecol; 1986 Jan; 93(1):22-7. PubMed ID: 3942702
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vasopressin effects on the uterus by a synthetic analogue.
Akerlund M; Strömberg P; Forsling ML; Melin P; Vilhardt H
Obstet Gynecol; 1983 Sep; 62(3):309-12. PubMed ID: 6877687
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women.
Akerlund M; Bossmar T; Brouard R; Steinwall M
Adv Exp Med Biol; 1998; 449():467-72. PubMed ID: 10026840
[No Abstract] [Full Text] [Related]
18. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus.
Nilsson L; Reinheimer T; Steinwall M; Akerlund M
BJOG; 2003 Nov; 110(11):1025-8. PubMed ID: 14592588
[TBL] [Abstract][Full Text] [Related]
19. Ge-Gen Decoction attenuates oxytocin-induced uterine contraction and writhing response: potential application in primary dysmenorrhea therapy.
Yang L; Chai CZ; Yue XY; Yan Y; Kou JP; Cao ZY; Yu BY
Chin J Nat Med; 2016 Feb; 14(2):124-132. PubMed ID: 26968678
[TBL] [Abstract][Full Text] [Related]
20. A randomized double blind comparison of atosiban in patients undergoing IVF treatment.
Ng EH; Li RH; Chen L; Lan VT; Tuong HM; Quan S
Hum Reprod; 2014 Dec; 29(12):2687-94. PubMed ID: 25336707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
